Opthea (ASX:OPT)
Company Profile
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Opthea.
RELATED STOCKHEAD STORIES
Health Check: FDA casualties mount as Trump’s ‘revolution’ takes place
Health Check: It’s a CEO changing of the guard at Mach 7 and Universal Biosensors
Health Check: Mayne Defenders fight ‘inadequate’ takeover offer
Scott Power: ASX health sector down in week of good and bad news
Health Check: Bargain hunters flock to 4D Medical’s discounted raising
Closing Bell: ASX inches into positive territory on diminished tariffs fears
Health Check: Opthea’s solvency in question after monumental phase III eye disease trial failure
Health Check: Emvision’s stroke detector takes to the skies
Health Check: These biotechs are awaiting key announcements on St Patrick’s Day
Scott Power: ASX health sector falls as market faces gathering storm clouds
ASX February health winners: Sector falls almost 8pc in weaker month for markets
Biocurious: With Mayne Pharmaceuticals under takeover offer, who’s next?
Health Check: With its last patient treated, Opthea eyes pending results of do-or-die trial
